Meeting
2020 ASCO Virtual Scientific Program
Selective targeting of HER2-overexpressing solid tumors with a next-generation CAR-T cell therapy.
Authors
Jenny Mu
Arcellx, Inc., Gaithersburg, MD
Jenny Mu , Justin Edwards , Liubov Zaritskaya , Jeffrey Swers , Ankit Gupta , David LaFleur , David Hilbert , Laura Richman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3041)
DOI
10.1200/JCO.2020.38.15_suppl.3041
Abstract #
3041
Poster Bd #
105
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.
First Author: Kim Anna Reiss
Poster
2021 ASCO Annual Meeting
A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.
First Author: Joshua Bauml
Poster
2024 ASCO Annual Meeting
The design, preclinical study and phase I dose escalation plan of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment.
First Author: Shanshan Jin
Poster
2023 ASCO Annual Meeting
Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
First Author: John Heymach